```
* * * * * * * * * * *   Welcome to STN International   * * * * * * * * * * *
 * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:57:40 ON 14 OCT 2008

=> file reg
=>Uploading C:\Program Files\Stnexp\Queries\Queries\10576972101408.str
```





```
chain nodes :
1  2  3  4  5  14  16  17  19  20  21  22
ring nodes :
6  7  8  9  10  11
chain bonds :
1-3  1-2  1-17  1-19  4-14  4-5  4-21  10-16  19-20  20-21  20-22
ring bonds :
6-7  6-11  7-8  8-9  9-10  10-11
exact/norm bonds :
1-3  1-2  1-17  1-19  4-14  4-5  4-21  6-7  6-11  7-8  8-9  9-10  10-11  10-16  19-
20  20-21  20-22
isolated ring systems :
containing 6 :


G1:H,Ak

G2:H,O

Match level :
1:CLASS  2:CLASS  3:CLASS  4:CLASS  5:CLASS  6:Atom  7:Atom  8:Atom  9:Atom
10:Atom  11:Atom  12:CLASS  14:CLASS  16:CLASS  17:CLASS  19:CLASS  20:CLASS
21:CLASS  22:CLASS




L1      STRUCTURE UPLOADED

=> s l1 sam
L2             0 SEA SSS SAM L1

=> s l1 full
L3            21 SEA SSS FUL L1

=> file caplus

=> s l3
L4             1 L3
```

```
=> dis l4 bib abs fhitstr

L4   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2008 ACS on STN
AN   2005:523469  CAPLUS  Full-text
DN   143:43971
TI   Preparation of phosphinic acid derivatives and their use as
     pharmaceuticals
IN   Froestl, Wolfgang
PA   Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SO   PCT Int. Appl., 16 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
PI   WO 2005054259        A1    20050616    WO 2004-EP13177        20041119
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO,
             SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
             NE, SN, TD, TG
     AU 2004295060         A1    20050616    AU 2004-295060         20041119
     AU 2004295060         B2    20070830
     CA 2545589            A1    20050616    CA 2004-2545589        20041119
     EP 1687319            A1    20060809    EP 2004-819605         20041119
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS
     CN 1882598            A     20061220    CN 2004-80034330       20041119
     BR 2004016226         A     20070102    BR 2004-16226          20041119
     JP 2007513088         T     20070524    JP 2006-540346         20041119
     US 20070259835        A1    20071108    US 2006-576972         20060425
     MX 2006PA05704        A     20060817    MX 2006-PA5704         20060519
     IN 2006CN01778        A     20070706    IN 2006-CN1778         20060519
     KR 807894             B1    20080227    KR 2006-709807         20060519
PRAI GB 2003-27186         A     20031121
     WO 2004-EP13177       W     20041119
OS   CASREACT 143:43971; MARPAT 143:43971
AB   The present invention relates to phosphinic acid derivs.,
     RP(O)(OH)CH2CHR1CH2NR2R3 (R = C3-5 alkyl, di(C1-4)alkoxymethyl, (C3-
     6)cycloalkyl(C1-4)alkyl or benzyl, etc.; R1 = H, OH; R2 =
     oxydihydropyridylmethyl, pyridylmethyl, etc.; R3 = H, C1-4 alkyl, or a salt
     thereof), as GABAB antagonists, their preparation, their use as
     pharmaceuticals and pharmaceutical compns. containing them.  Thus, reaction of
     Et {3-[(6-methoxy-3-pyridylmethyl)amino]-2-(S)-hydroxypropyl}-
     (cyclohexylmethyl)phosphinate (preparation given) with NaOH in EtOH/H2O gave
     phosphinic acid hydrochloride which on treatment with propylene oxide in MeOH
     gave title compound, {3-[(6-methoxy-3-pyridylmethyl)amino]-2-(S)-
     hydroxypropyl}-(cyclohexylmethyl)phosphinic acid.
IT   853654-59-8P
     RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
     (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
     (Uses)
```

(preparation of phosphinic acid derivs. and their use as pharmaceuticals)
RN 853654-59-8 CAPLUS
CN Phosphinic acid, (cyclohexylmethyl)[(2S)-2-hydroxy-3-[[(6-methoxy-3-pyridinyl)methyl]amino]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y
STN INTERNATIONAL LOGOFF AT 13:59:12 ON 14 OCT 2008